Modulation of mu-opioid pathway for the treatment of pruritus: a systematic review of 1,146 patients.
J Dermatolog TreatApr 27, 2026 (epub)
Clinical ResearchDermatology
Khalid M A Ahmed, Amro Abu Suleiman, Alaa I Alnajdawi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review analyzed the efficacy and safety of μ-opioid pathway modulators for treating pruritus in 1,146 patients across various dermatologic and systemic conditions. The review included 14 randomized controlled trials and found that most agents led to clinically meaningful reductions in pruritus intensity, indicating their potential as effective treatments for refractory itch.
Key findings
- Most RCTs showed clinically meaningful reductions in pruritus intensity using validated itch scales.
- Non-randomized studies reported improvement in pruritus across a wide range of conditions.
- Adverse events were generally mild and well tolerated.
Why it matters
Pruritus can significantly impact patients' quality of life, and conventional treatments often fall short. Understanding the role of μ-opioid pathway modulators may provide clinicians with new options for managing refractory itch effectively.